To analyze the consequences of this upregulation, we isolated A375-GFP melanoma cells from tumor-bearing mice treated with the BRAF inhibitor vemurafenib (100 mg/kg) for 12 days, at which point the tumor response was reaching a plateau (Figure 1C). This evidence concerns the gene BRAF and melanoma.